Members Trust’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.48M | Sell |
5,893
-363
| -6% | -$78.1K | 0.05% | 44 |
|
|
2026
Q1 | $1.36M | Sell |
6,256
-766
| -11% | -$170K | 0.05% | 44 |
|
|
2025
Q4 | $1.6M | Sell |
7,022
-321
| -4% | -$73.1K | 0.05% | 37 |
|
|
2025
Q3 | $1.7M | Sell |
7,343
-4
| -0.1% | -$815 | 0.06% | 34 |
|
|
2025
Q2 | $1.36M | Sell |
7,347
-197
| -3% | -$36.6K | 0.05% | 34 |
|
|
2025
Q1 | $1.58M | Buy |
7,544
+223
| +3% | +$43.4K | 0.06% | 30 |
|
|
2024
Q4 | $1.3M | Sell |
7,321
-18
| -0.2% | -$3.31K | 0.04% | 29 |
|
|
2024
Q3 | $1.45M | Sell |
7,339
-1,013
| -12% | -$189K | 0.05% | 27 |
|
|
2024
Q2 | $1.43M | Buy |
8,352
+4,533
| +119% | +$751K | 0.04% | 28 |
|
|
2024
Q1 | $695K | Buy |
3,819
+585
| +18% | +$101K | 0.02% | 50 |
|
|
2023
Q4 | $500K | Sell |
3,234
-400
| -11% | -$58.3K | 0.01% | 59 |
|
|
2023
Q3 | $553K | Sell |
3,634
-176
| -5% | -$25.8K | 0.02% | 52 |
|
|
2023
Q2 | $513K | Buy |
+3,810
| New | +$559K | 0.01% | 56 |
|
|
2022
Q4 | – | Sell |
-4,924
| Closed | -$661K | – | 38 |
|
|
2022
Q3 | $661K | Buy |
4,924
+565
| +13% | +$81.1K | 0.02% | 43 |
|
|
2022
Q2 | $668K | Buy |
4,359
+136
| +3% | +$20.8K | 0.02% | 45 |
|
|
2022
Q1 | $685K | Sell |
4,223
-1,050
| -20% | -$153K | 0.02% | 54 |
|
|
2021
Q4 | $714K | Buy |
5,273
+531
| +11% | +$62.7K | 0.02% | 53 |
|
|
2021
Q3 | $516K | Buy |
4,742
+400
| +9% | +$45.7K | 0.02% | 65 |
|
|
2021
Q2 | $489K | Sell |
4,342
-305
| -7% | -$34.4K | 0.02% | 73 |
|
|
2021
Q1 | $503K | Sell |
4,647
-454
| -9% | -$48.6K | 0.02% | 66 |
|
|
2020
Q4 | $547K | Buy |
5,101
+120
| +2% | +$11.5K | 0.02% | 61 |
|
|
2020
Q3 | $436K | Sell |
4,981
-93
| -2% | -$8.76K | 0.02% | 63 |
|
|
2020
Q2 | $498K | Buy |
+5,074
| New | +$447K | 0.02% | 54 |
|
|
2018
Q1 | $663K | Buy |
7,004
+1,605
| +30% | +$176K | 0.03% | 39 |
|
|
2017
Q4 | $522K | Buy |
5,399
+785
| +17% | +$74K | 0.03% | 43 |
|
|
2017
Q3 | $410K | Buy |
4,614
+172
| +4% | +$13.1K | 0.02% | 52 |
|
|
2017
Q2 | $322K | Sell |
4,442
-126
| -3% | -$8.47K | 0.02% | 59 |
|
|
2017
Q1 | $298K | Buy |
+4,568
| New | +$287K | 0.02% | 64 |
|
|
2016
Q3 | $303K | Buy |
4,803
+228
| +5% | +$14.8K | 0.02% | 58 |
|
|
2016
Q2 | $283K | Buy |
+4,575
| New | +$279K | 0.02% | 64 |
|
Other funds holding ABBV
ECSS
ATO
Members Trust's ABBV Position: Q2 2026 in Review
Members Trust reduced its AbbVie (ABBV) stake by 5.8% in Q2 2026, selling an estimated $78.1K and leaving 5,893 shares worth $1.48M. The position accounts for 0.05% of the portfolio, ranked #44.
Members Trust first reported a position in ABBV in Q2 2016 and has held it in 30 quarters since. The position peaked at $1.7M in Q3 2025. 2,119 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Members Trust held 5,893 shares of AbbVie worth $1.48M as of Q2 2026.
- Members Trust sold 363 AbbVie shares in Q2 2026, an estimated $78.1K.
- AbbVie made up 0.05% of Members Trust's portfolio in Q2 2026, its #44 holding.
- Members Trust first reported a position in AbbVie in Q2 2016 and has held it in 30 quarters since.
- Members Trust's AbbVie position peaked at $1.7M in Q3 2025.
- 2,119 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Members Trust's 13F filing for Q2 2026, filed 31 Jul 2026.